Jessica Donington, MD, MSCR: There’s one more factor that in 2021 plays a huge role in how we determine upfront treatment and treatment plans altogether and that’s something called molecular testing.

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, ...

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers. Joshua Sabari, MD: I recommend testing up front. All patients with ...

IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...

Genomic testing matters in endometrial cancer both for prognostication and therapeutic selection, but there's work to do in making sure it reaches all women. "It is a very exciting time for ...

ROCKVILLE, Md. – March 31, 2025 – The Association for Molecular Pathology, the premier global molecular diagnostic professional society, and pathologist Michael Laposata , M.D. , Ph.D., today ...

Antimicrobial resistance (AMR) remains a major global healthcare challenge, undermining the effectiveness of treatments for common infections and threatening modern medical advances. Improved ...

Please provide your email address to receive an email when new articles are posted on . During the past 2 decades, Endocrine Today has reported on the latest developments in treating thyroid cancer.